Elephas’ Cybrid™ platform helps pharmaceutical and biotechnology researchers accelerate immunotherapy drug development through the use of human live tumor fragments (hLTF)™ with the native tumor architecture and immune cells intact.
Within two weeks*, we can measure the impact of your compound on a tumor and its immune cells to help you gain insights and understand the impact on the patient.
Cybrid™ generates an array of outputs, including cytokine profiling, cellular markers, transcriptome analysis, and advanced 3D imaging using multiphoton microscopy and optical coherence tomography.
*<20 patient samples, time from receipt of test article
working with elephas
Elephas will support your studies from initial design through final data readouts. Along with the wealth of data our technology suite will provide, your team will have direct access to our expert cancer biologists and analysts. This unique connection is vital in setting our partners ahead of competitors and ensuring the highest probability of success for assets.